Clinical Trials Logo

Clinical Trial Summary

The objective of this study is to assess the Safety and Immunogenicity of PXVX0317 (Chikungunya Virus-Like Particle Vaccine [CHIKV VLP], alum-adjuvanted).


Clinical Trial Description

Primary Objectives: 1. To assess the induction of anti-CHIKV neutralizing antibody responses following a single adjuvanted dose of PXVX0317 (40 µg CHIKV VLP, alum-adjuvanted) as measured 21 days (Day 22) after vaccination. 2. To assess the induction of anti-CHIKV neutralizing antibody responses following a single adjuvanted dose of PXVX0317 as measured 7 days (Day 8), 14 days (Day 15), and 56 days (Day 57) after vaccination. Secondary Objectives: 1. To assess safety of a single adjuvanted dose of PXVX0317 in healthy adults. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05065983
Study type Interventional
Source Emergent BioSolutions
Contact Sarah Butts
Phone 650-486-0257
Email [email protected]
Status Recruiting
Phase Phase 2
Start date October 11, 2021
Completion date January 2022

See also
  Status Clinical Trial Phase
Recruiting NCT05072080 - A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 Phase 3
Terminated NCT00391313 - CuraChik : A Trial of the Efficacy and Safety of Chloroquine as Therapeutic Treatment of Chikungunya Disease Phase 3
Completed NCT02305732 - A Prospective, Open Label, Treatment Use Study of Patient Safety Following Transfusion of INTERCEPT Platelet Components
Completed NCT01489358 - Chikungunya Virus Vaccine Trial in Healthy Adults Phase 1
Completed NCT03325075 - Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Subjects Phase 1